我們已在上線！進一步了解

Gilead Sciences

GILD

市值 US$1937億

156.19 USD

-1.18

0.75%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

156.84

+0.65

0.42%

1天

-0.75%

5天

2.86%

1個月

5.76%

3個月

14.59%

6個月

12.73%

今年迄今

28.45%

1年

32.53%

5年

137.01%

10年

115.02%

關於： Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

員工： 17,000

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 55.6%

中性 37%

負面 7.4%

Zacks Investment Research

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts

Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2026 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for o.

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Zacks Investment Research

Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?

Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.

Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

The Big 3: MRK, GILD, XOM

The significant rotation in the AI trade, particularly in neoclouds like CoreWeave (CRVW), is something Dan Deming believes opens the door to new trading opportunities. He sees Merck (MRK) leading a stabilizing healthcare sector, Gilead Sciences (GILD) as a stock "poised to continue upward price action," and Exxon Mobil (XOM) as a high-liquid name in a booming energy trade.

The Big 3: MRK, GILD, XOM

Zacks Investment Research

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

24/7 Wall Street

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Zacks Investment Research

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Zacks Investment Research

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

查看新聞排名

價格圖表採用Lightweight Charts™實作